You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Merck
Medtronic
Dow
Mallinckrodt

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 8,486,938

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,486,938
Title:Pyrazolo[1,5-a]pyrimidines for antiviral treatment
Abstract: The invention provides compounds of Formula I or Formula II: ##STR00001## or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.
Inventor(s): Babaoglu; Kerim (Pacifica, CA), Boojamra; Constantine G. (San Francisco, CA), Eisenberg; Eugene J. (San Carlos, CA), Hui; Hon Chung (San Mateo, CA), Mackman; Richard L. (Milbrae, CA), Parrish; Jay P. (Redwood City, CA), Sangi; Michael (Oakland, CA), Saunders; Oliver L. (San Mateo, CA), Siegel; Dustin (Foster City, CA), Sperandio; David (Palo Alto, CA), Yang; Hai (San Mateo, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:13/167,618
Patent Claims:see list of patent claims

Details for Patent 8,486,938

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Medimmune SYNAGIS palivizumab VIAL 103770 001 1998-06-19   Start Trial Gilead Sciences, Inc. (Foster City, CA) 2030-06-24 RX search
Medimmune SYNAGIS palivizumab VIAL 103770 002 1998-06-19   Start Trial Gilead Sciences, Inc. (Foster City, CA) 2030-06-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
McKinsey
Johnson and Johnson
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.